Oncology

Latest News

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

Midkine May Play Key Role in SCLC

By Jared Kaltwasser

July 24th 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

By Maggie L. Shaw
David Nguyen, MD

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

By Mary Caffrey

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

July 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

January 2nd 2013

Expert Roundtable Panel Discussion: The Future of Payer Management of Oncology

December 31st 2012

December 31st 2012

Oncology, Innovation, and Healthcare

This article is based on the keynote address by Clifford Goodman, PhD

December 31st 2012

Developing Comparative Effectiveness Research in Oncology

This article is based on the presentation by Jeffrey D. Dunn, PharmD, MBA

December 31st 2012

Practical Application of Clinical Pathways

This article is based on the presentation by Bruce A. Feinberg, DO

December 31st 2012

Quality Measures in Oncology

This article is based on the presentation by Ira M. Klein, MD, MBA, FACP

December 31st 2012

Innovative Payment Models in Oncology Care

This article is based on the presentation by Peter B. Bach, MD, MAPP

December 31st 2012

Data Tracking and Point of Service Decision Support

This article is based on the presentation by Andrew L. Pecora, MD, FACP, CPE

December 31st 2012

Healthcare, the National Debt, and Taxes

This article is based on the presentation by Michael E. Chernew, PhD

Richard T. Hoppe, MD, Discusses the Current Role and Utility of Radiation Therapy

December 9th 2012

Richard T. Hoppe, MD, Discusses the Current Role and Utility of Radiation Therapy

Richard T. Hoppe, MD, Professor of Radiation Oncology - Radiation Therapy, Stanford School of Medicine, discussed the current role and utility of radiation therapy in patients with early stage Hodgkins Lymphoma when compared to conventional chemotherapy.

December 6th 2012

Bigger Role Seen for Breast Cancer Drug

November 30th 2012

Appendix A -- Value of Survival Gains in Chronic Myeloid Leukemia

November 30th 2012

Dynamic Cost-Effectiveness of Oncology Drugs

Yang Lu, PhD John R. Penrod, PhD Neeraj Sood, PhD Saarah Woodby, BA Tomas Philipson, PhD

November 30th 2012

Value of Survival Gains in Chronic Myeloid Leukemia

Wesley Yin, PhD John R. Penrod, PhD J. Ross Maclean, MD Darius N. Lakdawalla, PhD Tomas Philipson, PhD

Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.

November 21st 2012

Payer Management of Oncology: An In-Depth Look

On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.

November 20th 2012

Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study

Katrina A.B. Goddard, PhD Erin J. Aiello Bowles, MPH Heather Spencer Feigelson, PhD, MPH Laurel A. Habel, PhD Sharon Hensley Alford, PhD Catherine A. McCarty, PhD, MPH Larissa Nekhlyudov, MD, MPH Adedayo A. Onitilo, MD, MSCR, FACP Alanna K. Rahm, PhD, MS Jennifer A. Webster, MS

Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.

November 20th 2012

Trends in the 2012 Eisai Oncology Digest: Insurance and Cost Obstacles in Cancer Treatment

This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned funded by Eisai Inc.

Payer Management of Oncology: An In-Depth Look

November 19th 2012

Payer Management of Oncology: An In-Depth Look

On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

November 19th 2012

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care

November 19th 2012

Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care

Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Attending Physician, Memorial Sloan-Kettering Cancer Center, states that any organizational change that shifts payment and risk to providers will improve quality.

November 19th 2012

Automated Telephone Calls to Enhance Colorectal Cancer Screening: Economic Analysis

David H. Smith, RPh, PhD Adrianne C. Feldstein, MD, MS Nancy Perrin, PhD A. Gabriela Rosales, MS David M. Mosen, PhD, MPH Elizabeth G. Liles, MD Jennifer L. Schneider, MPH Jennifer E. Lafata, PhD Ronald E. Myers, PhD Russell E. Glasgow, PhD

Automated telephone calls can increase colorectal cancer screening rates at a cost of about $40 per additional screen.

Mark Fendrick, MD, Discusses Value-Based Insurance Design

November 19th 2012

Mark Fendrick, MD, Discusses Value-Based Insurance Design

Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care.

Michael Chernew, PhD, Discusses Challenges in Oncology Management

November 16th 2012

Michael Chernew, PhD, Discusses Challenges in Oncology Management

Michael Chernew, PhD, Professor of Health Care Policy, Harvard Medical School, Vice Chairman, MEDPAC, Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives.

Ira Klein, MD, Discusses Quality Measures in Oncology

November 16th 2012

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.

Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships

November 16th 2012

Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships

Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management.

November 13th 2012

Celgene Stock Soars on Promising Pancreatic Cancer Drug Data

November 12th 2012

Not Enough Cancer Drugs, Too Many Price Controls

October 29th 2012

Pricey New Prostate Cancer Therapy Raises Questions About Safety, Cost

October 24th 2012

Change to FIT Increased CRC Screening Rates: Evaluation of a US Screening Outreach Program

Elizabeth G. Liles, MD, MSCR Nancy Perrin, PhD Ana Gabriela Rosales, MS Adrianne C. Feldstein, MD, MS David H. Smith, RPh, MHA, PhD David M. Mosen, PhD, MPH Jennifer L. Schneider, MPH

Fecal immunochemical testing resulted in higher colorectal cancer screening rates than did guaiac fecal occult blood tests, with less dependence on office visits.

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

October 11th 2012

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

In this video, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.

...

176 177 178 179 180 181 182 183 184

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions